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Background: Intake of industrially produced trans fatty acids (TFAs) is, according to observational studies, associated with an
increased risk of cardiovascular disease, but the causal mechanisms have not been fully elucidated. Besides inducing
dyslipidemia, TFA intake is suspected to promote abdominal and liver fat deposition.
Objective: We examined the effect of a high intake of TFA as part of an isocaloric diet on whole-body, abdominal and hepatic fat
deposition, and blood lipids in postmenopausal women.
Methods: In a 16-week double-blind parallel intervention study, 52 healthy overweight postmenopausal women were
randomized to receive either partially hydrogenated soybean oil providing 15.7gday
 1 of TFA or a control oil with mainly oleic
and palmitic acid. Before and after the intervention, body composition was assessed by dual-energy X-ray absorptiometry,
abdominal fat by magnetic resonance (MR) imaging, and liver fat by
1H MR spectroscopy.
Results: Compared with the control fat, TFA intake decreased plasma high-density lipoprotein (HDL)-cholesterol by 10%,
increased low-density lipoprotein (LDL)-cholesterol by 18% and resulted in an increased LDL/HDL-cholesterol ratio (baseline
adjusted mean (95% CI) difference between diet groups 0.41 (0.22; 0.60); Po0.001). TFA tended to increase the body fat (0.46
( 0.20; 1.17) kg; P¼0.16) and waist circumference (1.1 ( 0.1; 2.4) cm; P¼0.08) more than the control fat, whereas neither
abdominal nor liver fat deposition was affected by TFA.
Conclusion: The adverse effect of dietary TFA on cardiovascular disease risk involves induction of dyslipidemia, and perhaps
body fat, whereas weight gain-independent accumulation of ectopic fat could not be identified as a contributory factor during
short-term intake.
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Introduction
A high intake of industrially produced trans fatty acids (TFAs)
has, in observational studies, consistently been shown to be
associated with an increased risk of coronary heart disease. In
a meta-analysis of four prospective cohort studies, it was
estimated that that an isocaloric substitution of 2% of the
total energy intake (E%) of carbohydrates with TFA corre-
sponds to a 23% increase in the risk of cardiovascular
events.
1
It has been well established that TFA intake increases the
ratio of total cholesterol (TC) to high-density lipoprotein-
cholesterol (HDL-C) in the blood. A recent meta-analysis
estimated that an absolute increase of 2 E% in the intake of
TFA is associated with an increase in the TC/HDL-C ratio of
B0.1 unit, when replacing cis monounsaturated fatty acids
(MUFAs).
2 An increase of this size is estimated to increase the
risk of coronary heart disease by B5%,
3 suggesting that TFA
exerts harmful effects beyond those affecting cholesterol
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www.nature.com/nutdconcentrations. Even when taking into account the possible
unfavorable effects of TFA on lipoprotein (a), triglycerides,
apolipoprotein (Apo) B/ApoAI ratio and C-reactive protein, a
considerable explanatory gap persists.
2 We hypothesize that
this gap might be partly explained by adverse effects of TFA
on body fat deposition.
Abdominal fat deposition is an established risk factor for
cardiovascular disease, and emerging evidence suggests that
liver fat should be considered to be one as well.
4 TFA intake
was positively associated with a modest increase in waist
circumference during 9 years of follow-up in the Health
Professional’s Follow-up Study, even after adjustment for
body mass index,
5 and with weight change during 8 years of
follow-up in the Nurses’ Health Study.
6 Moreover, a recent
intervention study in non-human primates suggested that
TFA might stimulate visceral fat deposition irrespective of
weight gain when consumed in considerable amounts over a
long period of time,
7 and rodent studies have shown that a
high TFA intake may lead to increased deposition of fat in
the liver.
8,9 In humans, it has yet to be examined whether
TFA intake affects abdominal or liver fat deposition.
We conducted a dietary intervention study with the
objective of examining the effect of a high intake of
industrially produced TFA on lipid deposition in liver and
in the abdominal region in TFA-depleted overweight post-
menopausal women. Also, we wished to confirm previous
findings of the effect of TFA on blood lipids.
Subjects and methods
The present work examined the effect of a high intake of TFA
on risk markers for cardiovascular disease, with the primary
end points being low-density lipoprotein-cholesterol (LDL-
C)/HDL-C ratio and liver fat deposition.
Study design
We conducted a 16-week double-blind, parallel dietary
intervention study, in which 52 women were randomized
to two test diets stratified by waist circumference. The cut-off
waist circumference was set at 96cm for separation into
strata. For each stratum a randomization sequence with
random permuted blocks of four was computer generated by
a third party prior to initiating the randomization. A coding
list was given to the department’s kitchen staff. The
investigators responsible for seeing the study subjects
allocated the next available number on entry into the trial,
and each woman collected her experimental diet directly
from the kitchen. Thereby the code was kept undisclosed for
the investigators until after study completion.
All study personnel and participants were blinded to the
treatment assignment for the duration of the study.
Information about which diet was assigned to which group
was not disclosed to the researcher responsible for the
statistical analyses before completion of the analyses.
The women visited the department for four examinations
during the study: at screening (1–8 weeks prior to baseline),
baseline (week 0), mid-intervention (week 8) and at the end
of treatment (week 16). In addition, the subjects attended
the department for control weighing at weeks 4 and 12. The
habitual physical activity level during the last year was
assessed at baseline using the questionnaire by Baecke et al.
10
and subjects were instructed to maintain their habitual
activity level throughout the dietary intervention period.
Subsequent to the dietary intervention period, the subjects
participated in a 12-week dietary weight loss program, after
which they came in for follow-up examinations. Data from
these examinations will be reported elsewhere.
Subjects attended all visits after an overnight fast of at least
10h. They were requested to avoid vigorous exercise and
alcohol consumption on the day before and on the day of
examinations at weeks 0, 8 and 16. Also, subjects were
instructed to consume similar evening meals on the evening
before the visits at weeks 0 and 16.
Subjects
The participating women were recruited from Copenhagen
and the surrounding areas by advertisements posted on
university web pages and in the local media. Subject
inclusion criteria were as follows: being healthy; being
moderately overweight (body mass index between 25 and
32kgm
 2); having a waist circumference 480cm; been
postmenopausal (self-reported) for the last 12 months; and
being aged 45–70 years, extremes included. The exclusion
criteria were the following: having diabetes or other chronic
diseases (active cancer, psychiatric disorders, moderate-
to-severe rheumatologic disorders, active gastrointestinal
disorders, chronic lung disease); having a history of cardio-
vascular disease; been smoking (currently and within
6 months prior to screening); having hypertension (4160/
100mmHg); having fasting plasma triglycerides
43mmoll
 1; having fasting plasma LDL-C 46mmoll
 1;
having fasting plasma glucose 47mmoll
 1; using hormones
or anti-hypertensive, anti-lipidemic or anti-cholesterolemic
drugs; having had weight changes 43kg for 2 months prior
to screening; participating in strenuous physical activity
410h per week; and having abnormalities in routine
biochemical and hematological tests. The subjects were not
allowed to donate blood during the study and 3 months
prior to screening, or to use fish oil as dietary supplements
during the study and 1 month prior to commencement.
To assess how adversely the metabolism of the interven-
tion group was affected by their elevated weight, the study
included 19 lean reference subjects (body mass index¼
19–24kgm
 2; waist circumference p80cm) who underwent
baseline examinations only. These reference subjects fulfilled
all other inclusion and exclusion criteria as the intervention
subjects.
The subjects were given both verbal and written informa-
tion, whereupon all gave written consent. The study was
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of Life Sciences, University of Copenhagen, Frederiksberg,
Denmark, between April 2008 and March 2009 and was
approved by the Municipal Ethical Committee of The
Capital Region of Denmark in accordance with the
Helsinki-II declaration (H-B_2007-089). Subjects received
B900 US$ as compensation on completion of all the tests.
Lean reference subjects received B500 US$. The trial was
registered at clinicaltrials.gov as NCT00655902.
Study diets
In this study, the physiological effect of consuming
15.7gday
 1 of industrially produced TFA from 26gday
 1
partially hydrogenated soybean oil was assessed, and a
50/50% mix of palm oil and high-oleic sunflower oil was
used as the control. Both test fats were supplied by
AarhusKarlshamn, Aarhus C, Denmark. The fatty acid (FA)
composition of the two test fats was analyzed chemically as
described below for red blood cell (RBC) FA composition. The
two fats mainly differed in the content of TFA, palmitic
(16:0), oleic (cis18:1n-9) and linoleic (cis, cis18:2n-6) acid
(Table 1). The test fats were incorporated into carrot bread
rolls, baked in the department’s metabolic kitchen. The
study participants were instructed to consume two bread
rolls per day, providing 26gday
 1 of test fat and a total of
2500kJ (approximately 7 E% protein, 41 E% fat and 51 E%
carbohydrate, calculated using the Dankost 3000 dietary
assessment software (Danish Catering Center, Herlev,
Denmark)). Frozen rolls were handed out to the women every
1–4 weeks from the department for consumption at home.
The intervention was not intended to promote weight
gain; hence, a clinical dietician instructed the participants
how to let the bread rolls iso-calorically substitute food items
from their habitual diets. The subjects were weighed every 4
weeks during the dietary intervention. They were offered an
additional dietary session if their weight increased more
than 2kg from baseline; three subjects from the TFA group
and two from the control group accepted the offer.
Compliance
At baseline the study subjects were handed a diary in which
they were to report whether or not both test rolls were
consumed each day. Also, they were to weigh back and
report the amounts not eaten. As an objective compliance
measure, the incorporation of FA into phospholipids of
RBCs was assessed at weeks 0, 8 and 16. For determination
of FA composition, saline-washed RBCs were spiked with
tri-heptadecenoylglyceride, solubilized in 9:1 methanol/
toluene and centrifuged. FA methyl esters in supernatant
aliquots were prepared by sequential treatment with an-
hydrous methanolic sodium methoxide and methanolic
hydrochloric acid.
11 FA methyl esters were back-extracted
into hexane, enriched with methyl tricosanoate (23:0) as an
internal standard, and quantified by gas chromatography on
high-polarity cyano-silica columns and a flame ionization
detector (see also Supplementary Methods).
Owing to co-chromatography of interference with variable
relative retention times on the two chromatographic systems
used during this study, an accurate quantitative assessment
of TFA concentrations could unfortunately not be made.
However, a qualitative ranking of the presence and abun-
dance of the TFA profile relative to cis18:1n-7 was possible
(Supplementary Figure 1).
Dietary intake
The dietary intake was assessed by 3-day weighed food
records before the intervention and in the last week of the
intervention. The records were coded, and the energy intake
and macronutrient composition were calculated by using a
national food database (National Food Agency, Søborg,
Denmark
12) with the Dankost 3000 dietary assessment
software (Danish Catering Center).
Anthropometrics and blood pressure
Body weight and waist and hip circumference were measured
at all visits. Body weight was measured in kilograms with one
decimal by a Lindeltronic 8000 scale (Samhall Lavi AB,
Kristianstad, Sweden). Height was assessed at screening to
the nearest 0.5cm using a Seca stadiometer (Hultafors,
Sweden). Waist circumference was measured at the midpoint
Table 1 Fatty acid composition of the two test fats
Fatty acid (w/w%) Control fat TFA fat
C14:0 0.7 0.2
C16:0 26.7 12.7
C16:1-trans (n-7)
a o0.1 o0.1
C16:1-cis (n-7) o0.1 o0.1
C17:0 o0.1 0.1
C18:0 3.8 6.2
Total C18:1-trans o0.7 59.0
trans (n-12)/trans (n-11)/ trans (n-10) o0.1 9.6
trans (n-9) o0.1 12.7
trans (n-8) o0.1 12.7
trans (n-7) o0.1 10.7
trans (n-6) o0.1 7.8
trans (n-5) o0.1 3.9
trans (n-4) o0.1 1.6
Total C18:1-cis 61.4 19.6
cis (n-12)/cis (n-11)/cis (n-10) o0.1 2.9
cis (n-9) 60.2 6.8
cis (n-8) o0.1 3.2
cis (n-7) 0.6 3.4
cis (n-6) 0.6 3.2
C18:2-trans, trans (n-6) o0.1 1.4
C18:2-cis, cis (n-6) 6.6 0.2
C20:0 0.4 0.4
C22:0 0.4 0.3
Total trans fatty acids o0.7 60.4
Abbreviation: TFA, trans fatty acid.
aPositions of double bonds are counted
from the methyl end of the fatty acid.
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Nutrition and Diabetesbetween the lower part of the last rib and the top of the hip,
and hip circumference at the maximal width over the greater
trochanters.
Blood pressure measurements were performed in the
seated position after 10min of rest, with an automatically
inflated cuff (UA-787, A & D, Saitama, Japan) at weeks 0, 8
and 16.
Body composition was measured by dual-energy X-ray
absorptiometry (DXA) using a GE Lunar Prodigy Advance
DXA scanner (GE Medical Systems Lunar, Madison, WI, USA).
A diagonal line passing through the middle of the femoral
neck separated the lower-body and trunkal regions for
determination of trunk fat as percentage of total tissue mass.
Magnetic resonance scans
We assessed total-, subcutaneous- and intra-abdominal
adipose tissue (AAT) volumes by magnetic resonance (MR)
imaging and measured the lipid content of the liver by
1H MR spectroscopy. MR examinations were performed on
all subjects at weeks 0 and 16 one to three days after the
other examinations (but on a similar day and time of day for
each subject at both visits). The subjects were instructed to
refrain from alcohol consumption and vigorous physical
activity for 24h prior to each scan. At the baseline visit
subjects recorded all food and drinks consumed the evening
before the scan and on the morning of the day of the scan.
At the subsequent visit this intake was to be replicated.
All MR measurements were performed using Achieva 3.0
T MR imaging system (Philips Medical Systems, Best, The
Netherlands) and a sense cardiac coil. At the beginning of
the MR examination, T2w TSE coronal and axial slices
through the abdomen were acquired for positioning the
spectroscopy volumes of interest. The spectroscopy volume
of interest (11mm 11mm) was positioned within the liver,
avoiding major blood vessels and intrahepatic bile ducts.
A single-voxel PRESS sequence with respiratory triggering
was used for acquisition. The MR scanner’s software was used
to fit the acquired spectrum to the relative content of water
and lipid. Thereby, hepatic lipid content was expressed as
lipid relative to water (%).
13
A fast T1w TFE MR sequence in transverse plane was used
to obtain data for estimating the adipose tissue volumes.
A transverse slice with 10mm thickness was acquired for all
subjects in the middle of the third lumbar vertebra (L3).
Image analysis to determine the total and intra-AAT fat
volumes was carried out on a Philips ViewForum workstation
using the ‘segmentation tool’ in ‘volume analysis’.
Blood sampling and analysis
Fasting blood was sampled from an antecubital vein after
minimum 10min of rest. Routine hematological and
biochemical analyses including blood lipids were performed
at the Department of Clinical Biochemistry, Gentofte
University Hospital, Denmark. Fasting plasma TC, HDL-C
and triglycerides were measured by dry chemistry slides
on Vitros 5.1 FS (Johnson & Johnson, Rochester, NY, USA).
The CV% values were 4.4, 6.0 and 9.6 for TC, HDL-C and
triglycerides, respectively. All tests were performed in
accordance with ISO 15189 accreditation. Plasma LDL-C
concentration was estimated by the Friedewald equation.
14
Statistical analyses
The study size was estimated based on the effect of TFA on
the LDL-C/HDL-C ratio. Based on data from two meta-
analyses, we assumed a within-subject s.d. of 0.6 for this
ratio.
1,15 We estimated that a minimum of 48 subjects was
required to detect an absolute difference of 0.5 in the LDL-C/
HDL-C ratio between diet groups with a statistical power of
80% and a two-sided significance level of 5%. Assuming an
s.d. for liver fat of 6.5% in moderately obese women,
16 a
difference between diet groups of approximately 6% point
liver fat could be detected with at a statistical power of
80%, a two-sided significance level of 5% and 24 expected
completers in each group. To allow for an estimated 10%
dropout rate, 52 participants were recruited.
Data were analyzed using Statistic Analysis Package, SAS
version 9.1 (SAS Institute, Cary, NC, USA). The primary
analysis included participants who completed the interven-
tion (n¼49). The statistical significance level was defined as
Po0.05.
Baseline values for the overweight intervention subjects
were compared with values for the lean reference subjects by
unpaired t-tests or Kruskal–Wallis tests for skewed data.
Analysis of covariance was used to assess the baseline-
adjusted difference between diet groups for variables mea-
sured at weeks 0 and 16, that is, the baseline value was
included as a covariate. For variables measured at weeks 0, 4,
8, 12 and 16 and weeks 0, 8 and 16, respectively, a mixed
model of repeated measures examining the effect of diet and
time (weeks 4, 8, 12 and 16) and their interactions was
applied, again with the baseline value as a covariate, and
with ‘subject’ treated as a random effect. Variance homo-
geneity and normality were investigated by residual plots,
histograms and Shapiro–Wilk’s test, and data were log
transformed when needed. Analyses were performed with
and without adjustment for changes in body weight.
Results
In all, 49 subjects (24 in the TFA group and 25 in the control
group) completed the intervention (Figure 1). One subject
withdrew immediately after baseline examinations (she felt
medicalized by the study) and two subjects dropped out after
a few weeks owing to lack of time. Baseline characteristics of
the subjects in the two diet groups were comparable and the
lean reference subjects were adequately matched for age and
height (Table 2).
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The test diets provided on average 28% of the subjects’
energy requirements. Self-reported compliance assessed
using study diaries showed that 98% of all test bread rolls
were consumed, with no difference between diet groups. The
presence of elevated trans18:1 residues in RBC phospholipids
determined by a gas chromatograph/flame ionization detec-
tor was used as an objective compliance measure. Owing to
an analytical interference, accurate quantification of
trans18:1 isomers was not possible. Instead, a qualitative
intensity scale was established and used to assign a value of
TFA enrichment to each sample (Supplementary Figure 1).
These results were transformed to ranks and showed that all
subjects in the TFA group had elevated trans18:1 residue
levels at both 8 and 16 weeks of intervention, whereas the
control subjects did not (Figure 2). The intervention
modestly decreased the relative abundance of saturated fatty
acids (SFAs) and increased that of polyunsaturated fatty acids
(PUFAs) in the RBCs of both diet groups after 16 weeks. Oleic
acid increased in the control group only (Supplementary
Table 1).
Dietary intake
The energy intake in the last week of the intervention
(representing the intake during the dietary period) was not
Assessed for eligibility (n = 64)
Excluded (n = 12)
Not meeting inclusion criteria (n = 8)
Refused to participate (n = 4)
Analyzed (n = 24)
Excluded from analysis (n = 0)
Lost to follow-up (n = 1)
Discontinued intervention (n = 0)
Allocated to intervention (n = 25)
Received allocated intervention (n = 24)
Did not receive allocated intervention (n = 1)
-one subject withdrew immediately after baseline.
Lost to follow-up (n = 2)
Discontinued intervention (n = 2)
-2 withdrew after 1-3  weeks due to lack of time.
Analyzed (n = 25)
Excluded from analysis (n = 0)
Allocation
Analysis
Follow-Up
Enrollment
Allocated to intervention (n = 27)
Received allocated intervention (n = 27)
Did not receive allocated intervention (n = 0)
CTR TFA
Figure 1 CONSORT flow diagram displaying subjects recruited into the dietary intervention. Subjects were randomly assigned into two diet groups: a trans fatty
acid (TFA) group and a control (CTR) group.
Table 2 Baseline characteristics for subjects in the TFA (n¼24) and control
(n¼25) groups and for lean reference subjects (n¼19)
a
TFA Control Lean reference
subjects
P
b
Age (years) 58.5±4.6 58.8±5.5 60.1±5.9 NS
Height (cm) 165.3±5.5 166.9±5.2 166.7±4.3 NS
Weight (kg) 78.7±7.1 78.4±8.6 59.4±4.8 o0.001
BMI (kgm
 2)2 8 . 8 ±1.7 28.1±2.2 21.3±1.4 o0.001
Waist circumference (cm) 97.1±7.3 95.5±6.8 74.9±3.8 o0.001
Blood pressure
Systolic (mmHg) 118±12 118±11 120±14 NS
Diastolic (mmHg) 81±88 2 ±68 0 ±10 NS
Physical activity index
10 7.5±1.4 7.9±1.6 8.6±1.4 0.02
Abbreviations: NS, not significant; TFA, trans fatty acid.
aValues are
means±s.d., completers only.
bP value refers to difference between over-
weight intervention subjects (diet groups combined) and lean reference
subjects by unpaired t-tests (P40.05).
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Figure 2 Semi-quantitative assessment of trans fatty acids (TFAs) in red
blood cell (RBC) phospholipids assessed by gas chromatography. Based on
semi-quantitative assessments of RBC trans18:1 profiles, including the scores
0, 0.5, 1, 1.5 and 2 (where 2 signifies full enrichment) (Supplementary
Figure 1), maximal TFA enrichment was observed by week 8 and was
generally sustained at week 16 in the TFA group (n¼24), whereas the subjects
in the control group experienced no TFA enrichment (n¼25). Changes from
baseline TFA profiles were assessed by repeated-measures ANOVA. Owing to
the non-normal distribution of the semi-quantitative data, the analyses were
performed on ranked data.
aSignificantly different from the baseline value
(Po0.001).
bSignificantly different from the control group (Po0.001).
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Nutrition and Diabetesdifferent between diet groups (Supplementary Table 2). The
only significant dietary differences between diet groups
during the intervention were the contributions of energy
from MUFA and TFA, indicating that the diets were overall
comparable apart from the FA composition. TFA constituted
7% of the energy intake in the TFA group.
Anthropometrics
Contrary to the intention, body weight increased slowly but
steadily in both diet groups during the dietary intervention,
with no difference between groups (P¼0.002 for effect of
time) (Figure 3). At week 16, mean (±s.e.m.) weight changes
from baseline in the TFA and control group were 1.1±0.2
and 1.1±0.3kg, respectively. Waist circumference tended to
increase more in the TFA group after adjustment for baseline
values (mean difference between diets 1.1cm (95% CI:  0.1
to 2.4cm); P¼0.08); adjusting for weight change had no
effect on this estimate (Figure 3). There was no difference
between groups in hip circumference (data not shown).
Fat deposition
The changes in whole body and trunk fat mass assessed by
DXA were in line with the trend for waist circumference. The
fat gain was numerically greater in the TFA group, although
not significantly so when compared with controls (Table 3).
The baseline adjusted mean difference in body fat between
diets at week 16 was 0.46kg (95% CI:  0.20 to 1.17kg;
P¼0.16).
Owing to technical reasons, the liver fat was obtained by
1H MR spectroscopy only in 23 subjects of each diet group,
and fat distribution was obtained by MR imaging in 19
subjects of each diet group. The dietary intervention did not
significantly affect the liver fat. The between-subject varia-
bility for liver fat changes was large (Figure 4), and thereby
the estimate of the liver fat concentration being 7% lower in
the TFA group at week 16 compared with controls, came
with a wide confidence interval (95% CI:  61 to 120%;
P¼0.87; Table 3). According to MR imaging, the dietary
intervention affected neither total-, subcutaneous-, intra-
AAT nor the ratio of intra- to subcutaneous AAT (Table 3). As
expected, the liver fat percentage as well as the subcuta-
neous- and intra-AAT volumes was significantly greater in
overweight subjects compared with lean reference subjects.
Plasma lipids
TFA adversely affected blood cholesterol by increasing LDL-C
and decreasing HDL-C (Table 4). Hereby, the ratio between
the two was significantly greater in the TFA diet group at
both weeks 8 and 16 compared with the control group
(baseline adjusted mean (95% CI) difference between diets
0.41 (0.22 to 0.60); Po0.001). Accordingly, the TC/HDL-C
ratio was also significantly increased by TFA (difference
between diets 0.45 (0.24 to 0.65); Po0.001). There was no
effect of diet on fasting plasma triglycerides.
Safety assessments
Blood pressure was stable in both diet groups during
the entire study period (data not shown). Hematological
(hemoglobin, thrombocytes, leucocytes and erythrocytes)
and biochemical (albumin, bilirubin, creatinine, sodium,
and potassium) blood parameters did not change during the
course of the study, nor did plasma liver enzymes (alanine
aminotransferase, aspartate aminotransferase and alkaline
phosphatase; data not shown).
Discussion
The present study aimed at decreasing the explanatory gap
between the harmful effects of industrially produced dietary
TFA seen in observational studies and the confirmed effects
on individual risk markers for cardiovascular disease. Owing
to the implementation of the Danish legislation, which went
into force in 2003 and practically eliminated industrially
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Figure 3 Development in mean (±s.e.m.) body weight (a) and waist
circumference (b)i nt h etrans fat (TFA; n¼24) and control (CTR; n¼25)
groups during the 16-week dietary intervention. Baseline values were not
significantly different (unpaired t-test, P40.05). Note that the y-axes have
been truncated. In spite of the isocaloric study design, body weight increased
significantly in both diet groups (P¼0.002 for effect of time in repeated-
measures analysis of covariance testing for interaction between diet group and
time (weeks 4, 8, 12, 16) with week 0 as a covariate; there was no significant
interaction between diet and time, nor effect on diet). Waist circumference
tended to increase more in the TFA group (P¼0.08 for effect of diet; there was
no significant interaction between diet and time, nor effect of time).
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study population was depleted of industrially produced TFA.
In metabolically vulnerable women, the present interven-
tion study found that a high intake of TFA from partially
hydrogenated soybean oil for 16 weeks increased the ratio of
plasma LDL- to HDL-C, but had no detectable effect on
hepatic and abdominal fat deposition.
In dietary interventions examining the effect of a specific
FA composition, it is always a challenge to decide on an
appropriate control fat. For the present study, a fat contain-
ing predominantly MUFA but also SFA and PUFA was chosen
because fast food products and snacks produced without TFA
have higher levels of all three FA classes compared with
similar products that are high in TFA.
17 Also, a recent report
has documented that when products high in TFA are
reformulated to eliminate TFA, the TFA is mainly replaced
by unsaturated FA.
18
TFA intake led to an increase in LDL-C as well as a decrease
in HDL-C concentrations. The mean difference between diet
groups in the TC/HDL-C ratio of 0.45 was somewhat larger
than what could have been expected from a recent meta-
analysis by Mozaffarian and Clarke
2 estimating that a
replacement of 1 E% TFA by SFA, MUFA and PUFA increases
the TC/HDL-C ratio by 0.031, 0.054 and 0.067, respectively.
2
The present study used a blend of palm oil and high oleic
sunflower oil as control fat, whereby 7 E% from TFA in the
TFA group was compared with an intake of 1.6 E% from SFA,
4.7 E% from MUFA and 0.7 E% from PUFA in the control
group. According to the estimates from the study by
Mozaffarian and Clarke, a difference in the TC/HDL-C ratio
of 0.35 between the TFA and control diet was expected. The
effect of TFA on blood lipids in the present study is also
considerably greater than that observed in our previous
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Figure 4 Liver fat percentage in the trans fat group (TFA; n¼23) and in the
control group (CTR; n¼23) before and after 16 weeks of dietary intervention
and in lean references (n¼19) obtained by
1H MR spectroscopy. Bars show
geometric means (95% confidence intervals). There was no significant effect
of diet, P¼0.87 for differences between diet groups at week 16 with week 0 as
a covariate, by analysis of covariance performed on log-transformed data. The
liver fat % in lean references was significantly lower than in overweight
intervention subjects (diet groups combined) by Kruskal–Wallis test for skewed
data; Po0.01.
Table 3 Body composition and abdominal fat deposition in the TFA and
control groups and in lean reference subjects
a
Week 0
b Week 16 ANCOVA
c
Pdiet
Fat mass (kg) 0.16
TFA (n¼24) 33.4±1.0 34.6± 1.1
Control (n¼25) 31.8±1.1 32.7±1.0
Lean reference subjects
(n¼19)
16.8±0.8
d NA
Fat-free mass (kg) 0.20
TFA (n¼24) 45.6±0.7 45.6±0.8
Control (n¼25) 47.0±1.0 47.3±0.9
Lean reference subjects
(n¼19)
43.3±0.6
d NA
Whole body fat (%) 0.12
TFA (n¼24) 42.1±0.7 43.0±0.7
Control (n¼25) 40.2±0.9 40.7±0.8
Lean reference subjects
(n¼19)
27.8±0.9
d NA
Trunk fat (%) 0.17
TFA (n¼24) 43.2±0.9 44.2±0.8
Control (n¼25) 41.3±1.0 42.0±0.9
Lean reference subjects
(n¼19)
25.5±1.1
d NA
Total AAT (cm
3)
e 0.85
TFA (n¼19) 446±20 458±20
Control (n¼19) 390±21 407±21
Lean reference subjects
(n¼19)
138±10
d NA
Subcutaneous AAT (cm
3)
e 0.46
TFA (n¼19) 313±15 317±15
Control (n¼19) 255±16 261±14
Lean reference subjects
(n¼19)
106±7.6
d NA
Intra-AAT (cm
3)
e 0.58
TFA (n¼19) 133±9 141±10
Control (n¼19) 135±14 146±17
Lean reference subjects
(n¼19)
33±4
d NA
Intra/subcutaneous AAT
e,f 0.67
TFA (n¼19) 0.45±0.04 0.46±0.05
Control (n¼19) 0.56±0.08 0.60±0.10
Lean reference subjects
(n¼19)
0.31±0.03
d NA
Liver fat (%)
f 0.87
TFA (n¼23) 2.7 (1.3; 5.7) 1.9 (0.8; 4.6)
Control (n¼23) 2.4 (1.0; 5.6) 1.8 (0.6; 5.1)
Lean reference subjects
(n¼19)
0.1 (0.07; 0.3)
d NA
Abbreviations: AAT, abdominal adipose tissue; ANCOVA, analysis of co-
variance; NA, not applicable; TFA, trans fatty acid.
aValues are means±s.e.m.
or geometric means (95% confidence interval) for skewed data, completers
only.
bThere were no significant differences in baseline values between diet
groups (unpaired t-test).
cP value refers to differences between diet groups at
week 16 with week 0 as a covariate, by ANCOVA. Adjusting for weight change
did not affect the results.
dSignificantly different from overweight intervention
subjects (diet groups combined) by unpaired t-test or Kruskal–Wallis test for
skewed data; Po0.05.
eObtained from MR imaging.
fANCOVA performed on
log10-transformed values.
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young men.
19 The fact that only moderately overweight
women above the age of 45 years were enrolled may help to
explain the more pronounced effect of TFA on plasma
cholesterol in the present study. It has previously been
suggested that a high TFA intake may be more detrimental
for women than for men.
20,21
The TC/HDL-C ratio is twice as informative of cardio-
vascular risk as TC or LDL-C alone.
3 The increase in the
TC/HDL-C ratio in the TFA group of 0.45 compared with the
control subjects may translate into an increase in the risk of
coronary heart disease of approximately 20%.
3 An intake
of 15gday
 1 of TFA may be a likely scenario in selected
communities or subpopulations around the world. For
example, in an Iranian population, the mean TFA intake
was as high as 12.3gday
 1 in 2001–2003,
22 and in 1989–91
the mean TFA intake in the US population was 5.3gday
 1
and 10% of the population was estimated to have an intake
above 9.4gday
 1.
23 However, although more recent intake
estimates are lacking, the TFA intake in the United States has
most likely declined in the recent years as increased trans fat
awareness has forced the food industry to limit the content
of TFA.
24
In prospective cohort studies, TFA intake has been
positively associated with changes in weight and waist
circumference.
5,6 In our study, women in both diet groups
experienced slight weight gains during the course of the
intervention, implying that they did not succeed in
isocalorically substituting the test food for food items from
their habitual diets. We observed weak trends toward greater
increases in waist circumference and total fat mass in the TFA
group compared with controls, independently of body
weight changes. However, these trends were not reflected
by the observed changes in abdominal fat deposition. We
saw no differences between the diet groups in either intra-
abdominal or subcutaneous abdominal fat deposition, nor in
the ratio between the two. Thereby, the present study could
not substantiate the findings from a study in green monkeys
observing an increase in the ratio of intra- to subcutaneous
AAT volume irrespective of weight gain after 6 years of
isocaloric TFA feeding.
7 It is likely that 16 weeks of exposure
was too short a period of time to detect changes in
Table 4 Blood lipids in the TFA (n¼24) and control (n¼25) groups and in lean reference subjects (n¼19)
a
Week 0
b Week 8 Week 16 ANCOVA
c
Ptime*diet Pdiet Ptime
Total cholesterol (mmoll
 1) 0.16 0.03 0.88
TFA 5.44±0.19 6.07±0.21 5.95±0.19
Control 5.54±0.20 5.77±0.18 5.86±0.21
Lean reference subjects 5.46±0.18 NA NA
HDL cholesterol (mmoll
 1) 0.23 0.03 o0.001
TFA 1.54±0.06 1.54±0.05 1.38±0.04
Control 1.65±0.07 1.69±0.08 1.59±0.06
Lean reference subjects 1.69±0.05 NA NA
LDL cholesterol (mmoll
 1) 0.24 0.002 0.01
TFA 3.39±0.18 3.91±0.19 4.01±0.18
Control 3.36±0.20 3.46±0.16 3.72±0.19
Lean reference subjects 3.47±0.17 NA NA
LDL/HDL-cholesterol ratio 0.23 o0.001 o0.001
TFA 2.31±0.16 2.64±0.17 3.02±0.20
Control 2.20±0.20 2.20±0.17 2.45±0.16
Lean reference subjects 2.08±0.11 NA NA
Total/HDL-cholesterol ratio 0.22 o0.001 o0.001
TFA 3.65±0.19 4.08±0.22 4.45±0.23
Control 3.54±0.23 3.60±0.21 3.83±0.20
Lean reference subjects 3.25±0.12 NA NA
Triglycerides (mmoll
 1)
d 0.78 0.39 0.09
TFA 1.13±0.10 1.39±0.15 1.24±0.09
Control 1.19±0.10 1.35±0.12 1.23±0.11
Lean reference subjects 0.67±0.04
e NA NA
Abbreviations: ANCOVA, analysis of covariance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not applicable; TFA, trans fatty acid.
aValues are
means±s.e.m., completers only.
bThere were no significant differences in baseline values between diet group (unpaired t-test, P40.05).
cP values were derived by
repeated-measures analysis of covariance testing for interaction between diet group and time (week 8, 16) with week 0 as a covariate. P values for effects of diet and
time, respectively, were derived from analyses omitting the interaction term.
dANCOVA performed on log10-transformed values.
eSignificantly different from
overweight intervention subjects (diet groups combined) by unpaired t-test; Po0.05.
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with high daily TFA intakes. Indeed, body weight gain may
be an intermediary step leading to TFA-induced increases in
abdominal fat deposition, which we may not have been able
to detect with our isocaloric study design. However, in
comparison, conjugated linoleic acid supplementation of
4.5gday
 1 has been shown to significantly decrease the fat
mass (assessed by DXA) in postmenopausal women within
16 weeks on isocaloric diets.
25 Also, isocaloric diets high in
PUFA have been found to significantly decrease subcuta-
neous AT (assessed by single-slice MRI) compared with diets
high in SFA within 5 weeks, despite no changes in body
weight.
26 This confirms that abdominal fat distribution can
be affected by dietary fat manipulations within the time-
frame of our study.
As a long-term dietary intervention study providing high
daily amounts of TFA is not feasible, it is questionable
whether an effect on abdominal fat will ever be established
in humans. Conversely, potential changes in liver fat due to
high intakes of TFA might be detected within a reasonable
period of time. Liver fat is suggested to be a more important
risk factor for obesity-related metabolic disorders than
intra-AAT.
27
We are the first to report on the influence of a high TFA
intake on liver fat deposition in humans. The data from the
present study were consistent with liver fat being from 61%
lower to 140% higher in the TFA group at week 16 when
compared with controls. Given the geometric mean liver fat
concentration of B2.5% at baseline, the confidence limits
may translate into an absolute mean decrease in liver fat of
1.5% or an absolute increase of 3.5%. Therefore, our results
cannot discount the possibility that TFA intake may exert
effects on liver fat smaller than this, prohibiting firm
conclusions on minor changes. However, no detectable
trend in liver fat was observed in either direction in either
diet group and plasma liver enzymes remained unchanged,
indicating that if TFA induced changes in liver fat concen-
tration, they were small indeed.
In several rodent studies TFA feeding has been shown to
increase liver fat by more than 100% compared with animals
fed cis FA,
8,9,28 although this is not a consistent finding.
29,30
Yet, extrapolation from animal studies is problematic.
Although it has been documented that liver fat deposition
in humans is affected by intake of energy and fat (liver fat
increased by 100% (from 2 to 4% and from 11 to 22%) after
3–4 days of hypercaloric high-fat diets
31,32 and by 35% (from
10 to 14%) after 14 days of eucaloric high-fat diets
33), the
influence of dietary FA composition on liver fat deposition in
humans has yet to be evaluated in controlled trials. It has,
however, been documented that intake of specific FAs
can affect liver fat accumulation; consumption of n-3 long
chain PUFA supplements (2–4gday
 1) for 8–26 weeks has
been shown to reduce liver fat in subjects with hepatic
steatosis.
34,35
Also, liver fat is affected by body weight changes and has
been shown to decrease by 30–60% in obese subjects after
B6–11kg weight loss.
36,37 In accordance, we observed
significant decreases of about 40% in liver fat mean values
after a 12-week dietary weight loss period (mean weight loss
B4kg) subsequent to the dietary intervention (data not
shown).
It is a strength of the present study that compliance with
the study diets was high, as reflected by the magnitude of
changes in plasma cholesterol concentrations. However, it
may be considered a limitation that the remaining part of
the participants’ diets was not strictly controlled. Results of
3-day food records collected in the last week of the
intervention were not indicative of significant differences
between diet groups in intake of either energy or any of the
macronutrients (Supplementary Table 2). Yet, we acknowl-
edge that minor differences may not have been picked up by
this dietary assessment.
It may also be considered a limitation that AAT volumes
were assessed by single-slice MRI, and not by examination of
the entire abdominal region. We obtained images at the level
of the third lumbar vertebra, which has been shown to be the
single-slice volume to correlate best with the intra-AATof the
whole abdominal region in women (R
2¼0.94–0.97).
38–40
However, single-slice methods may be less likely to detect
small changes in abdominal adiposity.
39,41
We measured liver fat by
1H MR spectroscopy, which is
the most accurate non-invasive technique available.
42
We aimed to standardize the liver fat assessments by
controlling alcohol intake, physical activity and diet from
the evening before the examination. However, the fact
that the diets were not controlled for longer periods before
the scans may have limited our ability to detect small
TFA-induced changes in liver fat. Also, as seen in Figure 4,
the between-subject variability in baseline liver fat was
large (range 0.1–73.0%), and it is questionable whether
subjects with very high liver fat content will be susceptible to
further increases due to dietary manipulations. In future
studies, a screening for liver fat content should be consid-
ered, since a modest diet-induced change may be more easily
detected in a study population with more homogeneous
liver fat levels.
In conclusion, our research confirms that part of the
increase in risk of cardiovascular disease seen with increased
TFA consumption in observational studies is likely to be
due to dyslipidemia. The magnitude of the observed
impact of TFA intake on blood cholesterol levels suggests
that older and overweight populations may be more
susceptible to TFA-induced metabolic changes than
young and lean ones. Conversely, weight gain-independent
induction of liver or intra-abdominal fat deposition
could not be identified as a contributory explanatory
mechanism.
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